426 completed, 242 unknown, 149 terminated, 88 withdrawn. 959 Phase 3, 278 Phase 2.
Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin for Long COVID Syndrome Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome | Phase 3 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 192 | 2026-12-01 | 2026-10-30 |
| The Study of Brave-LC LDN Treatment Trial naltrexone, Placebo - Post-acute COVID-19 Syndrome | Phase 3 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 1300 | 2026-11-16 | 2026-11-04 |
| A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease Secutrelvir, Placebo - SARS-CoV-2 | Phase 3 | Recruiting | Shionogi | 2000 | 2026-09-14 | 2026-11-03 |
| A Study of COVID-19 Vaccine(s) in Children and Adults BNT162b2 - COVID-19 Vaccines | Phase 3 | Recruiting | BioNTech SE | 700 | 2026-08-31 | 2026-09-28 |
| Study of Secutrelvir in Participants With COVID-19 Secutrelvir, Placebo - COVID-19 | Phase 3 | Recruiting | Shionogi | 1200 | 2026-08-05 | 2026-09-02 |
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline) - COVID-19 | Phase 3 | Completed | Invivyd, Inc. | 210 | 2026-06-08 | 2026-10-14 |
| sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 Fluvoxamine, Placebo - Post-COVID, POST-Covid 19 | Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 160 | 2026-06-04 | 2026-06-09 |
| Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) Baloxavir, Placebo Control - Influenza A, Influenza B | Phase 3 | Recruiting | Unity Health Toronto | 264 | 2026-04-29 | 2026-08-18 |
| A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition REGENECYTE, Placebo - Long COVID, Post-COVID-19 Condition | Phase 3 | Not yet recruiting | StemCyte, Inc. | 60 | 2026-03-31 | 2025-09-23 |
| Study of VYD2311 for the Prevention of COVID-19 VYD2311-SD, VYD2311-MD, Placebo - COVID-19 | Phase 3 | Active not recruiting | Invivyd, Inc. | 1770 | 2026-01-08 | 2026-06-10 |
| A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age BNT162b2 Vaccine, Placebo - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | BioNTech SE | 5240 | 2025-12-10 | 2026-10-16 |
| Taurine Supplementation in Long COVID Taurine, Placebo - Long COVID | Phase 2 / Phase 3 | Recruiting | University of Alberta | 300 | 2025-11-18 | 2026-09-18 |
| A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 BNT162b2 (2025/2026 formulation) - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | BioNTech SE | 344 | 2025-10-30 | 2026-08-07 |
| Safety and Immunogenicity of NVX-CoV2705 NVX-CoV2705 - COVID-19, SARS-CoV-2 Infection | Phase 3 | Completed | Sanofi | 676 | 2025-10-09 | 2026-06-05 |
| Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study Pirfenidone, Placebo for pirfenidone, Upadacitinib - Long COVID | Phase 3 | Recruiting | Douglas D. Fraser | 348 | 2025-09-10 | 2026-10-06 |
| A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised ibuzatrelvir, remdesivir, placebo for ibuzatrelvir - COVID-19 Infection | Phase 3 | Recruiting | Pfizer | 300 | 2025-07-14 | 2026-10-14 |
| A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | BioNTech SE | 774 | 2025-07-08 | 2026-06-01 |
| Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 Low-dose sirolimus, Placebo - Long COVID-19 | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 80 | 2025-04-18 | 2026-05-18 |
| A Study of Apabetalone in Subjects With Long -COVID Apabetalone - Post-Acute COVID-19 Syndrome | Phase 2 / Phase 3 | Recruiting | Resverlogix Corp | 200 | 2025-04-15 | 2025-04-18 |
Showing 20 of 959. Sign in to see all of them.
COVID-19 (909) · Severe Acute Respiratory Syndrome (66) · Pneumonia (44) · Post-Acute COVID-19 Syndrome (34) · Virus Diseases (34) · Respiratory Distress Syndrome (29) · Cytokine Release Syndrome (20) · Pneumonia, Viral (20) · RNA Virus Infections (18) · Coronaviridae Infections (17) · Respiratory Tract Infections (16) · Nidovirales Infections (15) · Respiratory Insufficiency (14) · Inflammation (12)
Infections (949) · Nidovirales Infections (944) · Coronaviridae Infections (942) · RNA Virus Infections (941) · Respiratory Tract Diseases (933) · Respiratory Tract Infections (925) · Virus Diseases (925) · Lung Diseases (924) · Pneumonia, Viral (914) · Pneumonia (890) · Pathological Conditions, Signs and Symptoms (106) · Pathologic Processes (88) · Respiration Disorders (47) · Disease Attributes (46)
Hydroxychloroquine (83) · Standard of Care (62) · remdesivir (40) · Azithromycin (32) · BNT162 Vaccine (32) · Ivermectin (28) · Sodium Chloride (26) · favipiravir (23) · Dexamethasone (21) · Saline Solution (21) · 2019-nCoV Vaccine mRNA-1273 (20) · COVID-19 Vaccines (17) · baricitinib (17) · ChAdOx1 nCoV-19 (15) · nitazoxanide (15)
National Institute of Allergy and Infectious Diseases (NIAID) (18) · Assistance Publique - Hôpitaux de Paris (16) · BioNTech SE (15) · Novavax (13) · ModernaTX, Inc. (11) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (9) · Ain Shams University (8) · AstraZeneca (8) · Gilead Sciences (8) · Pfizer (8) · Susanna Naggie, MD (8) · Murdoch Childrens Research Institute (7) · Cairo University (6) · Clover Biopharmaceuticals AUS Pty (6) · Promomed, LLC (6)
United States (247) · Brazil (110) · Spain (88) · Mexico (77) · France (67) · United Kingdom (64) · Canada (61) · Russia (55) · Argentina (53) · Italy (53) · South Africa (52) · China (46) · Germany (45) · Colombia (44) · Japan (41)
Adrian Hernandez, MD (9) · Susanna Naggie, MD (8) · James Neaton, Prof. (6) · Jens Lundgren, Prof. (6) · Prof. James Neaton (4) · Andy Goren, MD (3) · Bart Rijnders, MD, PhD (3) · Flavio Cadegiani, MD (3) · Hongxing Pan, Master (3)
PMID 34473343, PMID 35713300, PMID 35244208, PMID 36695483, PMID 37489818, PMID 34350582, PMID 37591523, PMID 33502773, PMID 34658014, PMID 31986264, PMID 32109013, PMID 32171076, PMID 33570583, PMID 35464483, PMID 35695334, PMID 36442063, PMID 25030060, PMID 32142651, PMID 32187464, PMID 32423584, PMID 32678530, PMID 33240091, PMID 33264556, PMID 33757717, PMID 34013969, PMID 37385888, PMID 38618926, PMID 39225478, PMID 15616839, PMID 32020029, PMID 32091533, PMID 32105632, PMID 32150748, PMID 32251768, PMID 32253318, PMID 32407672, PMID 32445440, PMID 32492293, PMID 32673060, PMID 32738928, PMID 32821939, PMID 33148977, PMID 33204764, PMID 33306283, PMID 33356051, PMID 33394942, PMID 34133856, PMID 34268513, PMID 34351721, PMID 34351722
2023 (10), U24TR001608 (8), P30CA138292 (2), 1OT2HD108097-01 (1), 1OT2HL156812 (1), 1OT2HL156812-01 (1), 2015 (1), 2018 (1), 3UL1TR002243-04S3 (1), R01AG085873 (1), R01DC021179 (1), R01HL146206 (1), U01HL123336 (1), U01HL123339 (1), U24HD092094 (1)